Ketamine/butamben topical - EpiCept

Drug Profile

Ketamine/butamben topical - EpiCept

Alternative Names: EpiCept™NP-2; NP-2

Latest Information Update: 13 May 2011

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Class Cyclohexanes; Local anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 13 May 2011 Discontinued - Phase-I/II for Neuropathic pain in USA (Topical)
  • 07 Jun 2005 Phase-I/II clinical trials in Neuropathic pain in USA (Topical)
  • 17 Mar 2003 Preclinical trials in Neuropathic pain in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top